KEQU — Q1 2026 Financial Report Analysis

Sales fell 6.7%, profit fell 45% — cost deleverage and a higher tax rate, not pricing

Kewaunee Scientific's first fiscal quarter of 2027 (the three months ended July 31, 2026 — the company's fiscal year ends April 30, so this quarter is reported alongside calendar 2026) was a demand problem, not a margin problem. Net sales of $66.3 million were down 6.7% from $71.1 million a year earlier, and the drop came from both reporting segments. Gross margin — the share of revenue left after the direct cost of making and installing the product — actually edged up, to 29.6% from 29.4%. What broke was everything below that line: operating costs stayed flat in dollars while the revenue they sit on shrank, and the tax rate jumped more than eight percentage points. Net earnings attributable to Kewaunee came in at $1.71 million, or $0.58 per diluted share, against $3.09 million and $1.04 a year ago.

Source: Condensed Consolidated Statements of Operations and Item 2 MD&A, Form 10-Q for the quarterly period ended July 31, 2026. Percentages calculated from the filed figures.

Why earnings fell almost seven times faster than sales

Three distinct things stacked up, and only one of them is about how the business is actually performing:

1. Operating cost deleverage. Operating expenses — selling, administration and engineering costs that don't scale down with a slow quarter — were $16.48 million, up $0.36 million from a year ago. Management's own description is that they "remained relatively flat." Flat dollars against $4.8 million less revenue means they consumed 24.9% of sales versus 22.7%, a 2.2-point hit that alone explains most of the $1.65 million decline in operating profit.
2. A much higher tax rate. The effective tax rate — the share of pre-tax profit actually paid in tax — was 28.0%, up from 19.4%. The filing attributes this to the mix of domestic versus foreign earnings taxed at different rates, a discrete benefit from restricted stock units vesting, and additional expense tied to the company's indefinite reinvestment assertion for its Indian subsidiary, Kewaunee Labway India. Holding the tax rate at last year's 19.4% and leaving everything else unchanged would have produced roughly $0.66 in diluted EPS instead of $0.58 (our calculation) — so about eight cents of the 46-cent decline is a tax-line effect rather than an operating one.
3. Interest expense working in the opposite direction. Interest expense dropped 40.8%, to $626,000 from $1,058,000. The mechanism is visible in the debt note: on December 4, 2025 Kewaunee repaid the $23.0 million of subordinated seller notes issued for the Nu Aire acquisition, which carried 8% paid-in-kind interest, funding it partly with a $10.0 million term loan from PNC priced off SOFR (5.19% at July 31, 2026). Swapping 8% seller paper for a ~5% bank term loan and paying down the balance is a permanent run-rate saving, and it is the one line that got materially better this quarter. Without it, the earnings decline would have been worse.

One item the filing does not explain: the corporate/eliminations bucket's pre-tax loss widened to $3.58 million from $3.06 million, even though the interest expense sitting in that bucket fell to $314,000 from $732,000. That implies roughly $0.9 million of higher unallocated corporate cost year over year, with no segment-level commentary attached to it. It is a small number in absolute terms but it is moving the wrong way while revenue shrinks.

Segments: domestic softness in life sciences, international margin improvement

Kewaunee reports two segments: Lab Products Group (LPG), the North American business that designs, makes and installs laboratory casework, fume hoods and worksurfaces, plus the Nu Aire biosafety-cabinet, incubator and ultralow-freezer lines acquired in November 2024; and International, the foreign subsidiaries that do laboratory design, engineering and project management, concentrated in India and the broader Asia-Pacific region.

The two segments moved in opposite directions on profitability. LPG sales fell 6.4%, which MD&A ties specifically to "lower demand in the domestic laboratory construction market, most notably in the life sciences market" — that is a capital-spending cycle in pharma and biotech lab construction, not a Kewaunee-specific share loss as far as this filing shows. International sales fell 7.8% "due to softer market conditions in India, partially offset by increased activity across the broader Asia-Pacific region," yet International pre-tax profit rose 18.5% on lower revenue, lifting its pre-tax margin by two points. Management identifies exactly that as the source of the consolidated gross-margin improvement: the change "was primarily driven by improved margin performance within the International segment." So the group's flat-to-better gross margin is carried by the smaller segment, while the segment that supplies 77% of revenue gave back 1.3 points of pre-tax margin.

The revenue-recognition split adds a detail worth watching. Sales recognized over time — long-running installation and project contracts — were $46.6 million, down 5.9%; sales recognized at a point in time — essentially product shipped, all of it within LPG — were $19.8 million, down 8.7%. The faster decline in point-in-time revenue suggests the Nu Aire-style equipment lines and other shipped product are feeling the slowdown at least as much as the project work.

Backlog: down 18% year over year, but no longer falling

For a company that builds to order as a subcontractor or supplier to dealers, backlog is the single most informative forward number in the filing. Kewaunee's order backlog was $169.0 million at July 31, 2026, against $205.0 million a year earlier and $165.9 million at April 30, 2026.

Two readings, and they genuinely conflict:

• Year over year, this is the warning. A $36 million, 17.6% smaller backlog is revenue that has already been decided not to exist. At the current quarterly run rate, $169.0 million is about 2.5 quarters of sales coverage, down from roughly 2.9 quarters a year ago. Backlog has led reported sales down, and the 6.7% revenue decline this quarter is the early part of that working through.
• Sequentially, the bleeding stopped. Backlog rose $3.1 million from the April 30 fiscal year-end. Since backlog grows by new orders and shrinks by revenue recognized, orders booked in the quarter were roughly $69.4 million against $66.3 million of revenue — an implied book-to-bill of about 1.05 (our estimate; the filing gives only the backlog balances, and the calculation assumes no material cancellations or currency effects inside the number, which it does not disclose separately). A book-to-bill above 1.0 means more work came in than went out.

Deferred revenue — customer money collected before the work is done — also rose, to $5.19 million from $4.15 million at April 30, consistent with new project activity starting rather than winding down.

Balance sheet: net debt down, revolver untouched, buybacks continuing

Kewaunee generated $1.98 million of cash from operations in the quarter, spent $0.77 million on capital expenditure, and used $2.50 million in financing — debt service, buybacks and employee tax withholding on vested stock. Cash fell to $8.25 million from $9.95 million at April 30. Term loan debt declined to $18.83 million from $20.08 million; the $20.0 million revolving credit facility was completely undrawn at both dates, and the company was in compliance with its covenants (senior debt to EBITDA no higher than 2.50x, fixed-charge coverage at least 1.20x). Working capital was $56.7 million with a current ratio of 2.2-to-1, unchanged from year-end.

The company bought back 14,290 shares during the quarter — 3,181 in June at an average $36.38 and 11,109 in July at $37.11 — leaving 86,313 shares authorized. That is a real use of cash for a company with 2.9 million shares outstanding, and it is why diluted share count fell to 2,921 thousand from 2,963 thousand even as basic shares rose. No dividend was declared. Goodwill from the Nu Aire deal stands at $12.5 million with no impairment recorded this quarter, and intangibles net of amortization at $15.9 million.

One forward commitment appears in the lease note: in August 2026 — after the quarter closed — Kewaunee signed a new lease not yet on the balance sheet, with aggregate future minimum payments of about $8.3 million over a 128-month term, expected to commence in the fourth quarter of fiscal 2027. That is a multi-year fixed cost being added while revenue is declining, though the filing does not say what facility it is for.

Outlook

Kewaunee gives no numerical guidance. Management's own framing is that "first quarter results for fiscal year 2027 align with the expectations previously communicated regarding the ongoing impact of broad geopolitical and economic uncertainty on project award and release timelines," that "these conditions may continue to influence the timing of project activity," and that "quoting activity remains strong across its markets." They also repeat the structural caveat that the company's "ability to predict future demand for its products continues to be limited given its role as subcontractor or supplier to dealers for subcontractors," and that earnings are exposed to steel, wood and epoxy resin prices.

Read plainly: management is describing a timing problem — projects being quoted but not released — rather than lost work. The sequential backlog uptick is the only hard number in the filing that supports that framing, and it is a single quarter of it.

Our read on trajectory: the next two or three quarters should still show year-over-year revenue declines, because the backlog Kewaunee is converting was booked when the balance was 18% higher. Margin direction is the more interesting question. Gross margin is holding — this is not a price war — so the earnings recovery depends on whether the $16.5 million quarterly operating cost base can be held flat, or trimmed, until revenue turns. If it can, the interest saving from retiring the 8% seller notes drops most of any revenue recovery through to the bottom line. The two things to check next quarter are whether backlog builds a second consecutive time (which would confirm orders have troughed) and whether the tax rate normalizes back toward the high teens or twenties, since roughly a sixth of this quarter's EPS decline came from that line alone.

Takeaway: The quarter's 45% earnings drop overstates what changed in the business — gross margin rose, interest cost fell 41% after the 8% seller notes were retired, and most of the damage came from flat operating costs spread over less revenue plus an 8.6-point jump in the tax rate. The number that actually matters for the next year is backlog: down 17.6% year over year, but up $3.1 million from April, an implied book-to-bill of roughly 1.05 that is the first evidence orders may have stopped shrinking.